OncoMatch/Clinical Trials/NCT06934382
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Is NCT06934382 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Allogeneic anti-CD7 CAR-T cells (BEAM-201) for t-cell acute lymphoblastic leukemia/lymphoma.
Treatment: Allogeneic anti-CD7 CAR-T cells (BEAM-201) — This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 expression (at least 90% of blasts positive)
Demographics
Prior therapy
Must have received: chemotherapy — induction and/or re-induction
second or greater relapse, first relapse post-transplant, or chemotherapy-refractory disease
Cannot have received: CD7 targeted therapy
Receipt of prior CD7 targeted therapy
Cannot have received: radiation therapy
Exception: prophylaxis for CNS disease
Radiation therapy within 2 weeks prior to completion of screening, other than prophylaxis for CNS disease
Lab requirements
Kidney function
Adequate Serum creatinine based on age/gender
Liver function
ALT ≤ 5x ULN in the absence of ALL infiltration of the liver; Bilirubin ≤ 3 × ULN for age (exceptions if abnormalities are directly related to ALL infiltration of the liver)
Cardiac function
ECHO with LVSF ≥ 30% or LVEF ≥ 50%; or qualitative normal ventricular function by cardiologist
Adequate organ function defined as: Adequate Serum creatinine based on age/gender; ALT ≤ 5x ULN in the absence of ALL infiltration of the liver; Bilirubin ≤ 3 × ULN for age... Cardiac echocardiography (ECHO) with left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06934382 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD7 targeted therapy, radiation therapy disqualifies patients from enrollment.
Does this trial require CD7?
Yes, CD7 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 29 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify